Literature DB >> 23269591

Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis.

Willem M Otte1, Monika Singla, Josemir W Sander, Gagandeep Singh.   

Abstract

OBJECTIVE: The effectiveness of anthelminthic and corticosteroid drug therapy in parenchymal neurocysticercosis is well established. The treatment of parenchymal solitary cysticercus granuloma (SCG), however, remains controversial. We attempted to obtain a consistent estimate of the efficacy of anthelminthic and corticosteroid drug treatment in SCG.
METHODS: Randomized-controlled trials (RCTs) comparing rates of seizure freedom, granuloma resolution, and residual calcification in individuals with SCG treated with anthelminthic or corticosteroid drugs with those treated with antiepileptic drugs (AEDs) alone were systematically reviewed and quantified using fixed- or random-effects meta-analysis.
RESULTS: Fifteen RCTs were identified for inclusion. Ten RCTs assigned 765 people with SCG to AED treatment with or without anthelminthic drug (albendazole) treatment. A further 5 RCTs assigned 457 people with SCG to AED treatment with or without corticosteroid drugs. Anthelminthic treatment was associated with significantly increased rates of seizure freedom (nonevent odds ratio: 2.45; 95% confidence interval: 1.49-4.03; p = 0.0004) and significantly higher rates of granuloma resolution (odds ratio: 2.09; 95% confidence interval: 1.41-3.00; p = 0.0003), but did not alter the risk of residual calcification. Corticosteroid treatment was not significantly associated with any outcome.
CONCLUSIONS: Anthelminthic treatment with albendazole provides improved rates of seizure freedom and hastens resolution of the granuloma. The role of corticosteroid treatment remains uncertain. The benefits (or lack thereof in the case of corticosteroids) are consistent when measured across different time points after treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269591      PMCID: PMC3589189          DOI: 10.1212/WNL.0b013e31827b90a8

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

1.  Neurocysticercosis in the United States: review of an important emerging infection.

Authors:  Christopher M DeGiorgio; Frank Sorvillo; Susan Pietsch Escueta
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

2.  Outcome of short-term antiepileptic treatment in patients with solitary cerebral cysticercus granuloma.

Authors:  A Verma; S Misra
Journal:  Acta Neurol Scand       Date:  2006-03       Impact factor: 3.209

3.  Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel.

Authors:  Oscar H Del Brutto; Karen L Roos; Christopher S Coffey; Héctor H García
Journal:  Ann Intern Med       Date:  2006-07-04       Impact factor: 25.391

4.  Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas.

Authors:  Sandeep Kaushal; Asha Rani; Sarvesh C Chopra; Gagandeep Singh
Journal:  Neurol India       Date:  2006-06       Impact factor: 2.117

5.  Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru.

Authors:  H H Garcia; R H Gilman; J Horton; M Martinez; G Herrera; J Altamirano; J M Cuba; N Rios-Saavedra; M Verastegui; J Boero; A E Gonzalez
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

Review 6.  Neurocysticercosis in the United States: review of an important emerging infection.

Authors:  Mitchell T Wallin; John F Kurtzke
Journal:  Neurology       Date:  2004-11-09       Impact factor: 9.910

7.  Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy.

Authors:  A Thussu; A Chattopadhyay; I M S Sawhney; N Khandelwal
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-10-10       Impact factor: 10.154

8.  Albendazole in neurocysticercosis.

Authors:  M V Padma; M Behari; N K Misra; G K Ahuja
Journal:  Natl Med J India       Date:  1995 Nov-Dec       Impact factor: 0.537

9.  Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study.

Authors:  Kamalesh Das; Gouranga Prasad Mondal; Mousumi Banerjee; Bansi Badan Mukherjee; Om Prakash Singh
Journal:  J Clin Neurosci       Date:  2007-10-26       Impact factor: 1.961

Review 10.  Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A Systematic review and meta-analysis.

Authors:  Maitreyi Mazumdar; Pari Pandharipande; Annapurna Poduri
Journal:  J Child Neurol       Date:  2007-02       Impact factor: 1.987

View more
  25 in total

Review 1.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

2.  A Personal Account Regarding the Origin and Evolution of Controversies in the Management of Neurocysticercosis.

Authors:  Oscar H Del Brutto
Journal:  Am J Trop Med Hyg       Date:  2019-04       Impact factor: 2.345

Review 3.  Neurocysticercosis.

Authors:  Pratibha Singhi; Renu Suthar
Journal:  Indian J Pediatr       Date:  2014-10-10       Impact factor: 1.967

4.  The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.

Authors:  Kriti Thapa; Matthew L Romo; Arturo Carpio; Denise Leslie; Howard Andrews; W Allen Hauser; Elizabeth A Kelvin
Journal:  Trans R Soc Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.184

5.  Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis.

Authors:  Arturo Carpio; Mindy Chang; Hongbin Zhang; Matthew L Romo; Alex Jaramillo; W Allen Hauser; Elizabeth A Kelvin
Journal:  Epilepsia       Date:  2019-07-29       Impact factor: 5.864

Review 6.  Update on the Diagnosis and Management of Neurocysticercosis.

Authors:  Camille M Webb; A Clinton White
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

Review 7.  Taenia solium Cysticercosis and Its Impact in Neurological Disease.

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

8.  Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after.

Authors:  Hector H Garcia; Isidro Gonzales; Andres G Lescano; Javier A Bustos; E Javier Pretell; Herbert Saavedra; Theodore E Nash
Journal:  Epilepsia       Date:  2014-08-04       Impact factor: 5.864

9.  Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.

Authors:  Hector H Garcia; Isidro Gonzales; Andres G Lescano; Javier A Bustos; Mirko Zimic; Diego Escalante; Herbert Saavedra; Martin Gavidia; Lourdes Rodriguez; Enrique Najar; Hugo Umeres; E Javier Pretell
Journal:  Lancet Infect Dis       Date:  2014-07-03       Impact factor: 25.071

Review 10.  The hidden genetics of epilepsy-a clinically important new paradigm.

Authors:  Rhys H Thomas; Samuel F Berkovic
Journal:  Nat Rev Neurol       Date:  2014-04-15       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.